| Identification | Back Directory | [Name]
Lokelma | [CAS]
17141-74-1 | [Synonyms]
Lokelma
1,3,5,2,4,6-trioxatrisilinane-2,2,4,4,6,6-hexaol disodium zirconium |
| Hazard Information | Back Directory | [Uses]
Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K+ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD)[1][2]. | [in vivo]
Sodium zirconium cyclosilicate (ZS-9; 2-6 g/kg; p.o.; daily, for 5 d) is a recovery in feces of Sprague-Dawley rats and can efficient uptake and removal of potassium ions[2]. | Animal Model: | Sprague-Dawley rats[2] | | Dosage: | 2, 4, and 6 g/kg | | Administration: | Oral administration; daily, for 5 days | | Result: | Had 99% fecal recovery in rats.
Uptake and removal of potassium ions in a dose-dependent manner.
|
| [References]
[1] Stavros F, et, al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686. DOI:10.1371/journal.pone.0114686
[2] Ash SR, et, al. A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404-11. DOI:10.1038/ki.2014.382 |
|
|